China's Burning Rock gets $23M to develop its cancer diagnostics

China's Burning Rock Biotech just completed a $23 million VC round in support of diagnostics for solid tumor cancers.

According to the company website, the company performs a variety of diagnostic tasks, including bioinformatics analysis and tumor molecular pathology conducted via next-generation sequencing, quantitative polymerase chain reaction, immunohistochemistry and fluorescence in situ hybridization and digital pathology.   

It aims to use those tools to gather information that enables personalized treatment of cancer.

The company is based in Guangzhou, a city in southeastern China, near Hong Kong.  

Investors in the latest round include Jifeng Capital, Sequoia Capital and Legend Star. The company was founded in March 2014, and last year raised $9.7 million in a Series A round from Northern Light Venture Capital and Legend Star. 

- here's more from the company website (translated from Chinese)

Suggested Articles

Millions of tests are urgently needed as the virus keeps communities across the country in lockdown and hospitals are overwhelmed with patients.

The FDA granted its first emergency authorization for a rapid antibody blood test for COVID-19 developed by Cellex.

The ultimate goal is to move as many patients as possible out of the clinic that don’t need immediate, critical care.